Skip to main content

Table 3 Correlation between TR expression and Immune infiltration was analyzed using TIMER. Significant values are in bold

From: Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy

Description

 

FABP4

ADIPOQ

PPARG

CD36

PPARGC1A

CREBBP

Purity

Rho

−0.24

−0.296

−0.211

− 0.249

0.06

0.013

p

1.35e-03

6.98e-05

5.05e-03

9.10e-04

4.29e-01

8.63e-01

B cell

Rho

−0.032

−0.059

−0.108

− 0.162

−0.038

0.009

p

6.72e-01

4.38e-01

1.56e-01

3.26e-02

6-23e-01

9.10e-01

CD8+

Rho

0

0.015

0.054

0.085

0.234

0.2

p

9.96e-01

8.74e-01

4.8e-01

2.65e-01

1.9e-03

8.10e-03

CD4+

Rho

0.251

0.264

0.027

0.128

0.038

0.138

p

8.30e-04

4.28e-04

7.2e-01

9.34e-02

6.14e-01

6.87e-02

Dendritic cells

Rho

0.111

0.09

−0.011

0.068

0.059

0.229

p

1.46e-01

2.38e-01

8.88e-01

3.72e-01

4.39e-01

2.39e-03

Cancer-associated fibroblasts

Rho

0.283

0.213

0.199

0.326

0.198

0.186

p

1.52e-04

4.74e-03

8.56e-03

1.12e-05

8.73e-03

1.4e-02

Macrophage

Rho

0.174

0.129

0.025

0.246

−0.145

−0.095

p

2.14e-02

9.07e-02

7.47e-01

1.08e-03

5.62e-02

2.21e-01

Neutrophils

Rho

−0.026

0.023

0.031

0.046

−0.095

0.19

p

7.34e-01

7.63e-01

6.87e-01

5.43e-01

2.14e-01

1.19e-02